Dipotassium 9-oxofluorene-2,7-disulfonate

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: Dipotassium 9-oxofluorene-2,7-disulfonate
• 英文别名: dipotassium;9-oxofluorene-2,7-disulfonate
• 化学式: C13H6K2O7S2
• 分子量: 416.5
• InChiKey: YTGCGUYEVMHLDO-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -5.29
• 重原子数：
  24
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  148
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• FLUORENONE/FLUORENOL DERIVATIVES FOR AQUEOUS REDOX FLOW BATTERIES
  申请人：Battelle Memorial Institute

  公开号：US20210147347A1

  公开（公告）日：2021-05-20

  Aqueous electrolytes comprising fluorenone/fluorenol derivatives are disclosed. The electrolyte may be an anolyte for an aqueous redox flow battery. In some embodiments, the compound, or salt thereof, has a structure according to any one of formulas I-III where Q 1 -Q 4 independently are CH, C(R 1 ) or N, wherein 0, 1, or 2 of Q 1 -Q 4 are N; Q 5 -Q 8 independently are CH, C(R 2 ), or N, wherein 0, 1, or 2 of Q 5 -Q 8 are N; Y is C═O or C(H)OH; R 1 and R 2 independently are an electron withdrawing group; n is an integer >1; and x and y independently are 0, 1, 2, 3, or 4, where at least one of x and y is not 0.

  披露了包括芴酮/芴醇衍生物的水性电解质。 该电解质可以用作水性氧化还原流动电池的阳极液。 在某些实施例中，化合物或其盐具有根据任一I-III式中的结构，其中Q1-Q4独立地为CH、C(R1)或N，其中Q1-Q4中的0、1或2个为N；Q5-Q8独立地为CH、C(R2)或N，其中Q5-Q8中的0、1或2个为N；Y为C═O或C(H)OH；R1和R2独立地为电子受体基团；n为大于1的整数；x和y独立地为0、1、2、3或4，其中x和y中至少一个不为0。
• NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NMPRTase) INHIBITOR FOR GLIOMA THERAPY
  申请人：Council of Scientific & Industrial Research

  公开号：EP2552444A1

  公开（公告）日：2013-02-06
• US9335332B2
  申请人：——

  公开号：US9335332B2

  公开（公告）日：2016-05-10
• [EN] NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NMPRTase) INHIBITOR FOR GLIOMA THERAPY<br/>[FR] INHIBITEUR DE NICOTINAMIDE PHOSPHORIBOSYLTRANSFÉRASE (NMPRTASE) POUR LA THÉRAPIE DE GLIOMES
  申请人：COUNCIL SCIENT IND RES

  公开号：WO2011121434A1

  公开（公告）日：2011-10-06

  The present invention relates to identification of a compound which inhibits the enzyme NMPRTase and glioma cancer cell growth and further used for glioma therapy. Pre-B- cell colony enhancing factor 1 gene (PBEF1) encodes nicotinamide phosphoribosyltransferase (NMPRTase), which catalyses the rate limiting step in the salvage pathway of NAD metabolism in mammalian cells. PBEF1 transcript and protein levels have been shown to be elevated in glioblastoma and a chemical inhibitor of NMPRTase has been shown to specifically inhibit cancer cells. Here a structure based drug discovery approach has been reported with an aim to develop novel inhibitors for glioblastoma therapy. Present invention relates to virtual screening using docking of ligands from a large library of 13,000 compounds against NMPRTase as the macromolecular target resulting in short listing of 34 possible ligands, of which six were tested experimentally, using the NMPRTase enzyme inhibition assay and further with the glioma cell viability assays. Of these, two compounds were found to be significantly efficacious in inhibiting the conversion of nicotinamide to NAD, and out of which one compound, 3-amino-2-benzyl-7-nitro-4-(2-quinolyl-)-l,2- dihydroisoquinolin-l -one, was found to inhibit the growth of a PBEF1 over expressing glioma derived cell line U87 also.